NI201100101A - Método para reducir trombocitopenia y mortalidad asociada a trombocitopenia. - Google Patents

Método para reducir trombocitopenia y mortalidad asociada a trombocitopenia.

Info

Publication number
NI201100101A
NI201100101A NI201100101A NI201100101A NI201100101A NI 201100101 A NI201100101 A NI 201100101A NI 201100101 A NI201100101 A NI 201100101A NI 201100101 A NI201100101 A NI 201100101A NI 201100101 A NI201100101 A NI 201100101A
Authority
NI
Nicaragua
Prior art keywords
thrombocytopenia
reduce
mortality associated
risk
mortality
Prior art date
Application number
NI201100101A
Other languages
English (en)
Inventor
Valgimigli Marco
Original Assignee
Iroko Cardio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42198725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100101(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iroko Cardio Llc filed Critical Iroko Cardio Llc
Publication of NI201100101A publication Critical patent/NI201100101A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen métodos para reducir el riesgo de mortalidad y morbilidad asociadas a trombocitopenia y para reducir el riesgo de trombocitopenia en pacientes cuyo tratamiento requiere inhibición de la agregación plaquetaria. Los métodos involucran la administración de una sal farmacéuticamente aceptable de tirofiban.
NI201100101A 2008-11-21 2011-05-20 Método para reducir trombocitopenia y mortalidad asociada a trombocitopenia. NI201100101A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11697608P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
NI201100101A true NI201100101A (es) 2011-12-19

Family

ID=42198725

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100101A NI201100101A (es) 2008-11-21 2011-05-20 Método para reducir trombocitopenia y mortalidad asociada a trombocitopenia.

Country Status (18)

Country Link
US (1) US20120059036A1 (es)
EP (1) EP2355824A4 (es)
KR (1) KR20110108330A (es)
AU (1) AU2009318101A1 (es)
BR (1) BRPI0920984A2 (es)
CL (1) CL2011001175A1 (es)
CO (1) CO6390039A2 (es)
CR (1) CR20110271A (es)
DO (1) DOP2011000149A (es)
EC (1) ECSP11011152A (es)
MA (1) MA32820B1 (es)
MX (1) MX2011005376A (es)
NI (1) NI201100101A (es)
PE (1) PE20110946A1 (es)
SV (1) SV2011003915A (es)
TN (1) TN2011000256A1 (es)
WO (1) WO2010059244A2 (es)
ZA (1) ZA201103741B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101996880B1 (ko) 2018-03-16 2019-07-05 경성대학교 산학협력단 컴파운드 k를 유효성분으로 포함하는 혈소판 감소증 예방 또는 치료용 조성물
CN112441962A (zh) * 2019-09-04 2021-03-05 武汉武药科技有限公司 替罗非班及其纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
HUP0303917A2 (hu) * 2001-01-26 2004-03-01 Schering Corporation Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
KR20050057294A (ko) * 2002-09-09 2005-06-16 트라이젠 리미티드 보론산 염, 및 혈전증의 치료를 위한 그것의 용도
KR20070032648A (ko) * 2004-05-12 2007-03-22 브리스톨-마이어스 스큅 컴퍼니 혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease

Also Published As

Publication number Publication date
WO2010059244A3 (en) 2010-10-14
ZA201103741B (en) 2012-01-25
US20120059036A1 (en) 2012-03-08
EP2355824A4 (en) 2012-11-07
PE20110946A1 (es) 2012-01-05
CL2011001175A1 (es) 2011-11-11
TN2011000256A1 (en) 2012-12-17
BRPI0920984A2 (pt) 2017-07-11
AU2009318101A1 (en) 2010-05-27
KR20110108330A (ko) 2011-10-05
EP2355824A2 (en) 2011-08-17
MX2011005376A (es) 2011-10-19
DOP2011000149A (es) 2011-10-31
CR20110271A (es) 2011-10-13
MA32820B1 (fr) 2011-11-01
CO6390039A2 (es) 2012-02-29
SV2011003915A (es) 2011-07-01
WO2010059244A2 (en) 2010-05-27
ECSP11011152A (es) 2011-09-30

Similar Documents

Publication Publication Date Title
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT201300234A (es) Sales de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
AR083865A1 (es) Composicion en gel para preparar un producto alimenticio
DOP2014000159A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
CL2013000218A1 (es) Forma de dosificacion farmaceutica para administracion oral de una vez al dia, que contiene 6’-fluoro-(n-metil- o n,n-dimetil)-4-fenil-4’,9’-dihidro-3’h-espiro[ciclohexan-1,1’-pirano[3,4,b]indol]-4-amina, para uso en el tratamiento del dolor nocioceptivo.
AR100006A1 (es) Derivados de tubulisina
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
RS53467B (en) USE OF AMISULPRID FOR TREATMENT OF Nausea and Vomiting Caused by Chemotherapy
CL2007003584A1 (es) Alimento para animales que utiliza krill como toda o parte de una fuente de proteina del alimento que comprende que se usa krill sin caparazon; y metodo para minimizar la reduccion en la tasa de crecimiento de los peces causada por el uso del krill c
CL2012003031A1 (es) Un metodo para administrar un lugar de investigacion de semillas.
AR082215A1 (es) Composicion farmaceutica agradable al paladar
EA201490199A8 (ru) Терапевтические способы
CU20140028A7 (es) Compuesto de benzotiazolona
NI201100101A (es) Método para reducir trombocitopenia y mortalidad asociada a trombocitopenia.
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral
UY32507A (es) Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib
UY35323A (es) Derivados sustituidos del ácido bisfenil butanóico como inhibidores de la nep con una mejorada efic acia in vivo
UY33431A (es) Sal de tirofibán y uso para reducir la trombacitopenia y mortalidad asociada a la trombocitopenia
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab
AR081639A1 (es) Una sal de tirofiban y uso de una cantidad efectiva de una sal de tirofiban farmaceuticamente aceptable para reducir la trombocitopenia y mortalidad asociada a la trombocitopenia
CL2013003671A1 (es) Composicion y combinacion farmaceutica que comprende ketorolaco y meloxicam; proceso para preparar la composicion; uso en el tratamiento de la inflamacion y el dolor.